BP
LYEL icon

BBR Partners’s Lyell Immunopharma LYEL Stock Holding History

BBR Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,834
Closed -$210K – 279
2025
Q4 		$210K Buy
+6,834
New +$153K 0.01% 248
2025
Q2 		– Sell
-8,202
Closed -$88.3K – 258
2025
Q1 		$88.3K Hold
8,202
– – 0.01% 233
2024
Q4 		$105K Hold
8,202
– – 0.01% 238
2024
Q3 		$226K Hold
8,202
– – 0.02% 208
2024
Q2 		$238K Hold
8,202
– – 0.02% 186
2024
Q1 		$366K Hold
8,202
– – 0.03% 169
2023
Q4 		$318K Hold
8,202
– – 0.03% 137
2023
Q3 		$241K Hold
8,202
– – 0.03% 163
2023
Q2 		$522K Hold
8,202
– – 0.06% 99
2023
Q1 		$387K Hold
8,202
– – 0.04% 110
2022
Q4 		$569K Hold
8,202
– – 0.06% 97
2022
Q3 		$1.2M Hold
8,202
– – 0.15% 65
2022
Q2 		$1.07M Hold
8,202
– – 0.13% 72
2022
Q1 		$828K Hold
8,202
– – 0.08% 106
2021
Q4 		$1.27M Buy
+8,202
New +$1.83M 0.15% 74

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBR Partners's LYEL Position: Q1 2026 in Review

BBR Partners sold out of Lyell Immunopharma (LYEL) in Q1 2026, closing a stake of 6,834 shares — an estimated $210K sold.

BBR Partners first reported a position in LYEL in Q4 2021 and held it in 15 quarters. The position peaked at $1.27M in Q4 2021. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • BBR Partners reported no remaining Lyell Immunopharma position as of Q1 2026 after selling out during the quarter.
  • BBR Partners sold 6,834 Lyell Immunopharma shares in Q1 2026, an estimated $210K.
  • BBR Partners first reported a position in Lyell Immunopharma in Q4 2021 and held it in 15 quarters.
  • BBR Partners's Lyell Immunopharma position peaked at $1.27M in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on BBR Partners's 13F filing for Q1 2026, filed 12 May 2026.